CareDx sharpens precision medicine focus with $260m Naveris acquisition

CareDx has agreed to get Naveris successful a woody worthy up to $260m, priming the institution to inherit a blood‑based monitoring solution for viral‑mediated cancers.

CareDx’s woody for the precision oncology diagnostics institution is structured with an upfront currency outgo of $160m, with the imaginable for an further $100m pending gross milestones. CareDx and Naveris expect the transaction to adjacent successful Q3 2026.

Naveris’s pb merchandise is NavDx, a liquid biopsy level based connected tumour insubstantial modified viral (TTMV) DNA. The trial measures fragments of viral DNA released from tumour insubstantial into the bloodstream and serves arsenic a biomarker successful quality papillomavirus (HPV)‑driven cancers.

Designed for tumour‑naïve investigating and diligent absorption from diagnosis done post‑treatment molecular residual illness (MRD) surveillance, NavDx obtained Medicare sum successful 2023. According to Naveris, the Massachusetts-based institution has performed 130,000 commercialized tests with NavDx to date.

In CareDx’s Q1 2026 financials, released connected 28 April, the company’s investigating services conception reported gross of $91m, corresponding to a 48% year-over-year (YoY) uptick. CareDx reported gross of $16m for its diligent and integer solutions conception versus $12m successful the aforesaid play of 2025.

Meanwhile, CareDx announced plans to divest its laboratory products concern to EuroBio Scientific successful a $170m woody connected 15 April. In Q1, CareDx said this conception was “relatively flat”, declining by 4% YoY to $10m.

CareDx’s determination to merchantability its laboratory products concern follows a akin determination by Thermo Fisher this week to merchantability its microbiology concern to Astorg successful a woody supra $1bn, suggesting a inclination of strategical realignment for immoderate players progressive successful the diagnostics space.

CareDx CEO John Hanna anticipates that the acquisition of Naveris volition accelerate its strategy to beforehand the maturation of its precision medicine investigating services and diligent and integer solutions concern segments.

Commenting connected the deal, Hanna said: “We are focused connected being a person successful concentrated speciality markets wherever a precocious load of illness drives repetition testing. Naveris fits that illustration with a differentiated exertion that is aboriginal successful its adoption.

“Naveris is poised for beardown growth, leveraging our halfway capabilities – gathering content successful molecular testing, simplifying objective workflow, and generating grounds for sum and reimbursement.”

Naveris CEO, James McNally, commented: “We are thrilled to beryllium combining forces with CareDx to fulfil our ngo of improving diligent outcomes by delivering disruptive exertion that transforms crab attraction and expanding diligent entree to precision medicine.”